Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

TxCell appoints Damian Marron Chief Executive Officer

Published: Wednesday, November 06, 2013
Last Updated: Wednesday, November 06, 2013
Bookmark and Share
Francois Meyer appointed Executive Chairman of the Board. TxCell SA announces the appointment of Damian Marron as CEO.

In addition, Francois Meyer, previously CEO, has been appointed Executive Chairman of the Board of Directors.

One of the main initial tasks for Damian Marron as CEO will be to guide the development of Ovasave(R), TxCell’s lead autologous Ag-Treg cell-based immunotherapy. Ovasave is currently in phase II development for the treatment of Crohn’s disease in patients who are refractory to current treatments. There are currently 160,000 such patients per year in Europe and in the US alone*.

TxCell’s strategy is to target niche and orphan indications for which there are few or no treatment options and a high unmet medical need. The company’s strong proprietary technology platform has so far demonstrated great promise in a number of chronic inflammatory and autoimmune conditions. Positive preliminary results for these indications have already been generated.

“At this stage of TxCell’s development, it has been critical for us to appoint a CEO who has both a high level of experience at working in niche and orphan market places with unmet medical needs, as well as for both private and public companies,” said Francois Meyer, Executive Chairman of the TxCell Board. “As a result, the Board members and I feel that Damian’s 26 years’ biotechnology and pharmaceutical experience will make him invaluable to TxCell’s medium and long term development. Damian’s proven management skills allied to his range of experience including financing, corporate development, product and technology licensing, research and development and sales and marketing will be instrumental for our strategy of building a leading cell therapy company with innovative personalized treatments for chronic inflammatory and autoimmune diseases.”

“TxCell has made great steps under the leadership of Francois Meyer in turning its cutting edge technology into a viable and recognized business model,” said Damian Marron. “I am delighted to combine my niche and orphan marketplace and biotechnology company management experience with that of the TxCell team, board and Francois to ensure that TxCell’s innovative approach will be brought to patients with serious conditions who have few or no therapeutic options.”

Damian Marron is a highly capable executive with 26 years strong experience in the orphan disease marketplace. Previously, he was CEO of Cytheris SA, a clinical stage biotechnology company focused on immunology through the development of IL-7 based therapeutics.

Prior to Cytheris, Damian was CEO of Trophos SA from 2008 to 2012. Under his tenure, Trophos spearheaded a group of major EU funded consortia of leading global experts and specialists working on a range of orphan diseases including Amyotrophic Lateral Sclerosis (ALS). He has also pushed through a Phase III trial for ALS and played a critical part in attracting EUR 34 million in funding. Damian was also instrumental in establishing and executing on a strategy that included an innovative exclusive option acquisition agreement with Actelion, worth an initial EUR 10 million and subject to milestones worth up to EUR 195 million.

Damian has also been Executive Vice President Corporate Development at NicOx SA. During that period, he was responsible for the establishment of major collaborations with Merck and Co. Inc. and Pfizer Inc. He also participated in financing rounds for NicOx, raising in excess of EUR 175 million.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TxCell to Present its Cellular Immunotherapy Developments
Dr. Miguel Forte and Dr. Arnaud Foussat will present at three forthcoming leading cell and gene therapy and ophthalmology conferences.
Friday, September 18, 2015
TxCell Granted US Orphan Drug Designation for Col-Treg
A first-in-man clinical study is planned to start in 2016, with top line results expected end 2017.
Tuesday, September 15, 2015
TxCell Announces Publication of Preclinical Efficacy Results for Col-Treg
Results published in Investigative Ophthalmology and Visual Science (IOVS) provide details on the demonstration of Col-Treg’s therapeutic potential in autoimmune uveitis and will support its ongoing clinical development.
Thursday, September 10, 2015
TxCell Receives Fast Track Designation from FDA for Ovasave®
TxCell’s lead product designated for the treatment of moderate to severe Crohn’s disease.
Wednesday, August 05, 2015
TxCell Appoints MaSTherCell for the Manufacturing of Ovasave®
First clinical batches could be manufactured as soon as Q2 2016.
Saturday, August 01, 2015
TxCell Announces FDA Acceptance of IND for Ovasave
IND grants TxCell option of extending current phase 2b study from EU to US.
Tuesday, June 30, 2015
TxCell Announces a Temporary Partial Hold of Activities at its Pilot Manufacturing Unit
Company expects only potential limited impact on clinical product timeline.
Wednesday, June 24, 2015
TxCell: Financial Information for the First Quarter of 2015
Company reports its revenues for 1Q 2015.
Thursday, May 14, 2015
TxCell Appoints Stéphane Boissel as Chief Executive Officer
Company promotes Miguel Forte to Chief Operating Officer.
Saturday, May 02, 2015
TxCell and Trizell Amend Collaboration Agreement
Company appoints the Cell Therapy Catapult to perform process and manufacturing development.
Friday, May 01, 2015
Strengthening of Cash Position and Development of ASTrIA Product Platform
Positive results for Col-Treg, second product candidate, in an auto-immune uveitis model.
Tuesday, April 07, 2015
TxCell to Present at Upcoming US and French Investment Conferences
Conferences include Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day, New York, March 25 and the Portzamparc PEA-PME Forum, Paris, April 1.
Saturday, March 28, 2015
Key TxCell Patent to be Granted in the US for its Lead Product Ovasave®
Patent ensures protection for Ovasave® in the US until 2030 minimum.
Thursday, March 19, 2015
TxCell to Present at ROTH Capital Partners Investor Conference in US
TxCell invited to speak at largest US meeting for investors in emerging growth companies.
Friday, February 27, 2015
TxCell Reports Revenues for 2014 and Updates on Upcoming Milestones
Ovasave and Col-Treg regulatory status update in the United States, expected mid-2015.
Thursday, February 05, 2015
Scientific News
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos